Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer

Eszter Podmaniczky, Katalin Fábián, Judit Pápay, Rita Puskás, Márton Gyulai, József Furák, L. Tiszlavicz, G. Losonczy, J. Tímár, Judit Moldvay

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We have already demonstrated in a small cohort of 17 non-small cell lung cancer patients that ERCC1 (excision repair cross-complementation group 1) protein expression decreased after platinum-based treatment, however, certain clinicopathological parameters, such as histologic subtypes, ERCC1 expression scores, chemotherapeutic combinations, response rate, gender and smoking history were not analyzed. The aim of our present study was to extend the studied cohort and analyze those parameters. ERCC1 protein expression was examined in 46 patients treated with neoadjuvant chemotherapy. 46 bronchoscopic biopsy samples (27 squamous cell carcinomas /SCC/ and 19 adenocarcinomas /ADC/) together with their corresponding surgical biopsies were studied. ERCC1 immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues. Staining scores were calculated by multiplying the percentage of positive tumor cells (0–100) by the staining intensity (0–3). 24/27 bronchoscopic SCC tissues expressed ERCC1. Thirteen of these cases became negative after neoadjuvant therapy and the expression differences between pre- and postchemotherapy samples were highly significant (p <0.001). 11/19 bronchoscopic ADC tissues expressed ERCC1. Six of these cases became negative after neoadjuvant therapy and the expression differences were significant (p <0.010). There was no newly expressed ERCC1 postoperatively. Comparison of staining score changes revealed more pronounced decrease in SCC (p = 0.032). We observed no correlation between initial ERCC1 level or ERCC1 decrease and overall survival, but we demonstrated correlations between decrease in ERCC1 expression and histologic subtypes of tumors and gender. We could confirm our previous data in a larger cohort that platinum-based chemotherapy affects the ERCC1 expression probably referring to an induction of tumor cell selection.

Original languageEnglish
Pages (from-to)423-431
Number of pages9
JournalPathology and Oncology Research
Volume21
Issue number2
DOIs
Publication statusPublished - Apr 28 2015

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
DNA Repair
Drug Therapy
Neoadjuvant Therapy
Staining and Labeling
Biopsy
Neoplasms
Paraffin
Formaldehyde
Squamous Cell Carcinoma
Proteins
Adenocarcinoma
Cohort Studies
Smoking
History
Immunohistochemistry
Survival

Keywords

  • ERCC1
  • Gender differences
  • Immunohistochemistry
  • Lung cancer
  • Platinum based chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Podmaniczky, E., Fábián, K., Pápay, J., Puskás, R., Gyulai, M., Furák, J., ... Moldvay, J. (2015). Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer. Pathology and Oncology Research, 21(2), 423-431. https://doi.org/10.1007/s12253-014-9839-x

Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer. / Podmaniczky, Eszter; Fábián, Katalin; Pápay, Judit; Puskás, Rita; Gyulai, Márton; Furák, József; Tiszlavicz, L.; Losonczy, G.; Tímár, J.; Moldvay, Judit.

In: Pathology and Oncology Research, Vol. 21, No. 2, 28.04.2015, p. 423-431.

Research output: Contribution to journalArticle

Podmaniczky, Eszter ; Fábián, Katalin ; Pápay, Judit ; Puskás, Rita ; Gyulai, Márton ; Furák, József ; Tiszlavicz, L. ; Losonczy, G. ; Tímár, J. ; Moldvay, Judit. / Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer. In: Pathology and Oncology Research. 2015 ; Vol. 21, No. 2. pp. 423-431.
@article{46e67c2a81c249568782b5fb4b9e82f3,
title = "Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer",
abstract = "We have already demonstrated in a small cohort of 17 non-small cell lung cancer patients that ERCC1 (excision repair cross-complementation group 1) protein expression decreased after platinum-based treatment, however, certain clinicopathological parameters, such as histologic subtypes, ERCC1 expression scores, chemotherapeutic combinations, response rate, gender and smoking history were not analyzed. The aim of our present study was to extend the studied cohort and analyze those parameters. ERCC1 protein expression was examined in 46 patients treated with neoadjuvant chemotherapy. 46 bronchoscopic biopsy samples (27 squamous cell carcinomas /SCC/ and 19 adenocarcinomas /ADC/) together with their corresponding surgical biopsies were studied. ERCC1 immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues. Staining scores were calculated by multiplying the percentage of positive tumor cells (0–100) by the staining intensity (0–3). 24/27 bronchoscopic SCC tissues expressed ERCC1. Thirteen of these cases became negative after neoadjuvant therapy and the expression differences between pre- and postchemotherapy samples were highly significant (p <0.001). 11/19 bronchoscopic ADC tissues expressed ERCC1. Six of these cases became negative after neoadjuvant therapy and the expression differences were significant (p <0.010). There was no newly expressed ERCC1 postoperatively. Comparison of staining score changes revealed more pronounced decrease in SCC (p = 0.032). We observed no correlation between initial ERCC1 level or ERCC1 decrease and overall survival, but we demonstrated correlations between decrease in ERCC1 expression and histologic subtypes of tumors and gender. We could confirm our previous data in a larger cohort that platinum-based chemotherapy affects the ERCC1 expression probably referring to an induction of tumor cell selection.",
keywords = "ERCC1, Gender differences, Immunohistochemistry, Lung cancer, Platinum based chemotherapy",
author = "Eszter Podmaniczky and Katalin F{\'a}bi{\'a}n and Judit P{\'a}pay and Rita Pusk{\'a}s and M{\'a}rton Gyulai and J{\'o}zsef Fur{\'a}k and L. Tiszlavicz and G. Losonczy and J. T{\'i}m{\'a}r and Judit Moldvay",
year = "2015",
month = "4",
day = "28",
doi = "10.1007/s12253-014-9839-x",
language = "English",
volume = "21",
pages = "423--431",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer

AU - Podmaniczky, Eszter

AU - Fábián, Katalin

AU - Pápay, Judit

AU - Puskás, Rita

AU - Gyulai, Márton

AU - Furák, József

AU - Tiszlavicz, L.

AU - Losonczy, G.

AU - Tímár, J.

AU - Moldvay, Judit

PY - 2015/4/28

Y1 - 2015/4/28

N2 - We have already demonstrated in a small cohort of 17 non-small cell lung cancer patients that ERCC1 (excision repair cross-complementation group 1) protein expression decreased after platinum-based treatment, however, certain clinicopathological parameters, such as histologic subtypes, ERCC1 expression scores, chemotherapeutic combinations, response rate, gender and smoking history were not analyzed. The aim of our present study was to extend the studied cohort and analyze those parameters. ERCC1 protein expression was examined in 46 patients treated with neoadjuvant chemotherapy. 46 bronchoscopic biopsy samples (27 squamous cell carcinomas /SCC/ and 19 adenocarcinomas /ADC/) together with their corresponding surgical biopsies were studied. ERCC1 immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues. Staining scores were calculated by multiplying the percentage of positive tumor cells (0–100) by the staining intensity (0–3). 24/27 bronchoscopic SCC tissues expressed ERCC1. Thirteen of these cases became negative after neoadjuvant therapy and the expression differences between pre- and postchemotherapy samples were highly significant (p <0.001). 11/19 bronchoscopic ADC tissues expressed ERCC1. Six of these cases became negative after neoadjuvant therapy and the expression differences were significant (p <0.010). There was no newly expressed ERCC1 postoperatively. Comparison of staining score changes revealed more pronounced decrease in SCC (p = 0.032). We observed no correlation between initial ERCC1 level or ERCC1 decrease and overall survival, but we demonstrated correlations between decrease in ERCC1 expression and histologic subtypes of tumors and gender. We could confirm our previous data in a larger cohort that platinum-based chemotherapy affects the ERCC1 expression probably referring to an induction of tumor cell selection.

AB - We have already demonstrated in a small cohort of 17 non-small cell lung cancer patients that ERCC1 (excision repair cross-complementation group 1) protein expression decreased after platinum-based treatment, however, certain clinicopathological parameters, such as histologic subtypes, ERCC1 expression scores, chemotherapeutic combinations, response rate, gender and smoking history were not analyzed. The aim of our present study was to extend the studied cohort and analyze those parameters. ERCC1 protein expression was examined in 46 patients treated with neoadjuvant chemotherapy. 46 bronchoscopic biopsy samples (27 squamous cell carcinomas /SCC/ and 19 adenocarcinomas /ADC/) together with their corresponding surgical biopsies were studied. ERCC1 immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues. Staining scores were calculated by multiplying the percentage of positive tumor cells (0–100) by the staining intensity (0–3). 24/27 bronchoscopic SCC tissues expressed ERCC1. Thirteen of these cases became negative after neoadjuvant therapy and the expression differences between pre- and postchemotherapy samples were highly significant (p <0.001). 11/19 bronchoscopic ADC tissues expressed ERCC1. Six of these cases became negative after neoadjuvant therapy and the expression differences were significant (p <0.010). There was no newly expressed ERCC1 postoperatively. Comparison of staining score changes revealed more pronounced decrease in SCC (p = 0.032). We observed no correlation between initial ERCC1 level or ERCC1 decrease and overall survival, but we demonstrated correlations between decrease in ERCC1 expression and histologic subtypes of tumors and gender. We could confirm our previous data in a larger cohort that platinum-based chemotherapy affects the ERCC1 expression probably referring to an induction of tumor cell selection.

KW - ERCC1

KW - Gender differences

KW - Immunohistochemistry

KW - Lung cancer

KW - Platinum based chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84938085242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938085242&partnerID=8YFLogxK

U2 - 10.1007/s12253-014-9839-x

DO - 10.1007/s12253-014-9839-x

M3 - Article

C2 - 25194563

AN - SCOPUS:84938085242

VL - 21

SP - 423

EP - 431

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -